ArticleTranslational cancer research2026
Pre-clinical anti-tumor activity and preliminary safety of METTL3 inhibitors STM2457 and UZH1a in neuroblastoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA mActa pharmacologica Sinica · 2026Review
- Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma.Cellular and molecular life sciences : CMLS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroblastoma (NB) is one of the most common malignant tumors in children, characterized by high heterogeneity and poor prognosis, posing notable therapeutic challenges. The objective of the present study was to investigate the therapeutic potential and safety profile of two N6-adenosine-methyltransferase 70 kDa subunit (METTL3) inhibitors, STM2457 and UZH1a, in NB. Methods: In this study, we utilized the SK-N-SH cells and wild-type AB strain zebrafish to investigate the anti-tumor efficacy of STM2457 and UZH1a in NB. Cell counting kit-8 (CCK-8), Transwell assays, apoptosis detection, and global N6-methyladenosine (m6A) quantification were performed following 24 h exposure of STM2457 or UZH1a in SK-N-SH cells. For zebrafish, acute-toxicity screening, hepatic enzyme measurement, and xenograft establishment were conducted. Total RNA from larvae was subjected to reverse transcription quantitative polymerase chain reaction for immune-regulatory genes and transcriptome sequencing to identify key pathways. Results: Conclusions: STM2457 and UZH1a exhibited potent anti-NB activity both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.